Core Insights - July 18 marked a significant day for the capital market with multiple key approvals from the China Securities Regulatory Commission (CSRC) [1] - The approvals indicate an acceleration in the review process for quality mergers and acquisitions, as well as a more inclusive approach for IPOs on the Sci-Tech Innovation Board [1][7] Group 1: Mergers and Acquisitions - The CSRC approved China Shipbuilding Industry Company’s absorption merger with China Shipbuilding Heavy Industry Company, marking a significant step in the integration of two major listed platforms under the China Shipbuilding Group [2] - The merger is the first to complete the Shanghai Stock Exchange review and CSRC registration under the new restructuring regulations, setting a precedent for future mergers [2] - ChipLink Integrated Circuit Manufacturing Co. received approval for a significant asset restructuring deal, involving the acquisition of 72.33% of ChipLink Yuezhou Integrated Circuit Manufacturing for a total transaction value of 5.897 billion yuan, despite both companies currently being unprofitable [2][3] Group 2: Initial Public Offerings (IPOs) - Wuhan Heyuan Biotechnology Co. became the first company to receive IPO registration approval under the newly restarted fifth set of standards on the Sci-Tech Innovation Board [4] - Heyuan Biotechnology plans to raise 2.4 billion yuan for the construction of a recombinant human albumin production base, new drug development, and to supplement working capital [5] - Shenzhen Beixin Life Technology Co. also passed the listing review under the new standards, focusing on high-performance innovative medical devices for cardiovascular interventions [5] - Yushu Technology has initiated the IPO counseling process, with plans for a comprehensive evaluation of its listing conditions by October 2025 [5][6]